Get to Know Dr. Travis E. Grotz
Innovative surgical oncologist Dr. Travis Grotz focuses on minimizing patient complications when treating gastrointestinal cancers and peritoneal malignancies, including mesothelioma, at the Mayo Clinic in Rochester, Minnesota.
Grotz often uses cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, also known as HIPEC, a procedure that has advanced treatment considerably in recent years. It has allowed some patients with peritoneal mesothelioma to survive a decade or more after diagnosis.
He specializes in novel, regional therapeutics and treatment sequencing for different cancers, often minimizing postoperative complications. His research has focused on various immunotherapies and clinical trials.
Grotz treats pancreatic, gastric, appendix and colon cancers. He also has expertise in liver and small bowel resections.
He is the principal investigator of a recently opened phase II clinical trial studying the use of HIPEC with advanced stage pancreatic cancer.
Specialties of Dr. Travis E. Grotz
- Cytoreductive surgery
- Minimally invasive surgery
- Pancreatic enucleation
- Small bowel resection
- Liver resection
- Peritoneal mesothelioma
- Stomach cancer
- Metastatic colorectal cancer
- Soft tissue sarcoma
- Immune thrombocytopenia
Dr. Travis E. Grotz’s Experience and Education
- Mayo Clinic Minnesota
- MD Anderson Cancer Center (Fellowship)
- Mayo Clinic (Residency)
- Mayo Clinic College of Medicine (M.D.)
Awards and Certifications
- Certified in complex general surgical oncology and general surgery
- Bronze Award, Mayo Clinic (2019)
- Promoting Excellence in Patient Care, MD Anderson Cancer Center (2017)
- Thomas H. and Mayme P. Scott Endowed Research Fellowship, MD Anderson Cancer Center (2016)
Publications of Dr. Travis E. Grotz
- Grotz, T.E. et al. (2021, March). Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study. Anesthesia.
- Yonkus, J.A., Alva-Ruiz, R. & Grotz, T.E. (2021, March 20). Surgical Management of Metastatic Gastrointestinal Stromal Tumors. Current Treatment Options In Oncology.
- Roife, D. et al. (2020, December). CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does Not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative. Annals of Surgical Oncology.
- Eng, O.S. et al. (2020, July 5). Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways. Journal of Surgical Oncology.
Thank you for your feedback. Would you like to speak with a Patient Advocate?